Related Experiment Video
Updated: Jun 5, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy
Takis Athanasopoulos1, Helen Foster, Keith Foster
1Institute of Biomedical and Life Sciences, South West London Academic Network, St. George's University of London, London, UK. P.Athanasopoulos@rhul.ac.uk
Abstract:
Duchenne muscular dystrophy (DMD) is a severe muscle wasting X-linked genetic disease caused by dystrophin gene mutations. Gene replacement therapy aims to transfer a functional full-length dystrophin cDNA or a quasi micro/mini-gene into the muscle. A number of AAV vectors carrying microdystrophin genes have been tested in the mdx model of DMD. Further modification/optimization of these microgene vectors may improve the therapeutic potency. In this chapter, we describe a species-specific, codon optimization protocol to improve microdystrophin gene therapy in the mdx model.
Related Concept Videos
Gene Therapy
Gene Therapy
Satellite Stem Cells and Muscular Dystrophy

